Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Protein Effect||gain of function|
|Gene Variant Descriptions||KDR act mut indicates that this variant results in a gain of function in the Kdr (Vegfr2) protein. However, the specific amino acid change has not been identified.|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KDR act mut||Advanced Solid Tumor||sensitive||Sorafenib||Preclinical||Actionable||In a preclinical study, Nexavar (sorafenib) demonstrated efficacy in cells expressing KDR activating mutations (PMID: 19723655).||19723655|
|KDR act mut||Advanced Solid Tumor||predicted - sensitive||Lucitanib||Phase I||Actionable||In a Phase I trial, Lucitanib (E-3810) demonstrated safety and efficacy in patients with FGF-aberrant or angiogenesis-sensitive advanced solid tumors (PMID: 25193991).||25193991|
|KDR act mut||Advanced Solid Tumor||sensitive||Sunitinib||Preclinical||Actionable||In a preclinical study, cells expressing KDR activating mutations were sensitive to Sutent (sunitinib) in cell culture (PMID: 19723655).||19723655|
|KDR act mut||bladder urothelial carcinoma||predicted - sensitive||Sunitinib||Phase II||Actionable||In a Phase II clinical trial of patients with metastatic urothelial cancer, Sutent (sunitinib) demonstrated limited antitumor activity, warranting further investigation of VEGF pathways as a therapeutic target (PMID: 20142593).||20142593|